Publication
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
dc.contributor.author | Marslin, Gregory | |
dc.contributor.author | Revina, Ann Mary | |
dc.contributor.author | Khandelwal, Vinoth Kumar Megraj | |
dc.contributor.author | Balakumar, Krishnamoorthy | |
dc.contributor.author | Prakash, Jose | |
dc.contributor.author | Franklin, Gregory | |
dc.contributor.author | Sheeba, Caroline Jeya | |
dc.date.accessioned | 2018-12-07T14:58:26Z | |
dc.date.available | 2018-12-07T14:58:26Z | |
dc.date.issued | 2015 | |
dc.description.abstract | Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could sustainably release the drug, and studied its efficacy by in vitro anticancer and in vivo cardiotoxicity assays. MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay revealed that INPs are more cytotoxic to MCF-7 breast cancer cells compared to the equivalent concentration of free imatinib mesylate. Wistar rats orally administered with 50 mg/kg INPs for 28 days showed no significant cardiotoxicity or associated changes. Whereas, increased alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels, and reduced white blood cell, red blood cell, and hemoglobin content were observed in the animals administered with free drug. While the histological sections from hearts of animals that received INPs did not show any significant cardiotoxic symptoms, loss of normal architecture and increased cytoplasmic vacuolization were observed in the heart sections of animals administered with free imatinib mesylate. Based on these results, we conclude that nano-encapsulation of imatinib mesylate increases its efficacy against cancer cells, with almost no cardiotoxicity. | |
dc.identifier.doi | 10.2147/IJN.S75962 | |
dc.identifier.issn | 1178-2013 | |
dc.identifier.uri | http://hdl.handle.net/10400.1/12026 | |
dc.language.iso | eng | |
dc.peerreviewed | yes | |
dc.publisher | Dove Medical Press | |
dc.relation | SHEDDING LIGHT ON THE CONTROVERSY: ESTABLISHING THE EMBRYO MOLECULAR CLOCK AS AN INTEGRAL COMPONENT OF THE LIMB PATTERNING MACHINERY | |
dc.subject | Tyrosine kinase nhibitor | |
dc.subject | Bcr-abl | |
dc.subject | Polymeric nanoparticles | |
dc.subject | Antitumor-activity | |
dc.subject | Doxorubicin | |
dc.subject | Toxicity | |
dc.subject | Growth | |
dc.subject | Cells | |
dc.subject | Combination | |
dc.subject | Therapy | |
dc.title | Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity | |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.awardTitle | SHEDDING LIGHT ON THE CONTROVERSY: ESTABLISHING THE EMBRYO MOLECULAR CLOCK AS AN INTEGRAL COMPONENT OF THE LIMB PATTERNING MACHINERY | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F72809%2F2010/PT | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT//SFRH%2FBPD%2F89493%2F2012/PT | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/COMPETE/PTDC%2FAGR-GPL%2F119211%2F2010/PT | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/5876/UID%2FAGR%2F04033%2F2013/PT | |
oaire.citation.endPage | 3170 | |
oaire.citation.startPage | 3163 | |
oaire.citation.title | International Journal of Nanomedicine | |
oaire.citation.volume | 10 | |
oaire.fundingStream | SFRH | |
oaire.fundingStream | COMPETE | |
oaire.fundingStream | 5876 | |
person.familyName | Sheeba | |
person.givenName | Caroline Jeya | |
person.identifier | 437977 | |
person.identifier.orcid | 0000-0001-5357-4743 | |
person.identifier.rid | B-5177-2011 | |
person.identifier.scopus-author-id | 6504257550 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
rcaap.rights | openAccess | |
rcaap.type | article | |
relation.isAuthorOfPublication | 6b2fbf4f-bd66-4f2e-99c8-1d5446d85a98 | |
relation.isAuthorOfPublication.latestForDiscovery | 6b2fbf4f-bd66-4f2e-99c8-1d5446d85a98 | |
relation.isProjectOfPublication | 7ab8894a-4dc9-40be-90dd-7cfcc440a308 | |
relation.isProjectOfPublication | 58e0d95f-782f-4c8a-b029-c2bc31090e5a | |
relation.isProjectOfPublication | e45767fb-80bb-4590-9f91-0677b87c85b7 | |
relation.isProjectOfPublication | 4da3841b-f509-4707-b296-a50b5898f9fa | |
relation.isProjectOfPublication.latestForDiscovery | 4da3841b-f509-4707-b296-a50b5898f9fa |
Files
Original bundle
1 - 1 of 1